ArticleCancer research2011
HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells.
Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.BMC cancer · 2013Pooled it
- Regulated HSPG Signaling Directs Epicardial Behavior to Support Cardiac Formation.Circulation research · 2026Article
- Review
- FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities.Theranostics · 2026Review
- Bioinformatic Approach to Identify Positive PrognosticInternational journal of molecular sciences · 2025Article
- DCN, NPM3 and SULF1 are hub genes related to vasculogenic mimicry in lung adenocarcinoma.Journal of cancer research and clinical oncology · 2025Article
- Therapeutic potential of hAMSCs in ligament regeneration: insights from the UCA1-miR-16-5p-FGF2 pathway.Stem cell research & therapy · 2025Article
- Heparin, Heparin-like Molecules, and Heparin Mimetics in Breast Cancer: A Concise Review.Biomolecules · 2025Review
- 6-O-endosulfatases in tumor metastasis: heparan sulfate proteoglycans modification and potential therapeutic targets.American journal of cancer research · 2024Review
- Role of Prosaposin and Extracellular Sulfatase Sulf-1 Detection in Pleural Effusions as Diagnostic Biomarkers of Malignant Mesothelioma.Biomedicines · 2022Article
- Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications.Molecular cancer · 2022Review
- Anticancer Effects of Herbal Medicine Compounds and Novel Formulations: a Literature Review.Journal of gastrointestinal cancer · 2020Review
- Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer.Biochemical pharmacology · 2020Article
- HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.International journal of oncology · 2020Article
- The HPA/SDC1 axis promotes invasion and metastasis of pancreatic cancer cells by activating EMT via FGF2 upregulation.Oncology letters · 2020Article
- Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation.International journal of molecular sciences · 2019Review
- MicroRNA-497-5p inhibits proliferation and invasion of non-small cell lung cancer by regulating FGF2.Oncology letters · 2019Article
- Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer.Frontiers in oncology · 2019Article
- Genome-wide DNA methylation profiles in Tibetan and Yorkshire pigs under high-altitude hypoxia.Journal of animal science and biotechnology · 2019Article
- Sulfatase-1 knockdown promotes in vitro and in vivo aggressive behavior of murine hepatocarcinoma Hca-P cells through up-regulation of mesothelin.Journal of cell communication and signaling · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
HSulf-1 modulates the sulfation states of heparan sulfate proteoglycans critical for heparin binding growth factor signaling. In the present study, we show that HSulf-1 is transcriptionally deregulated under hypoxia in breast cancer cell lines. Knockdown of HIF-1α rescued HSulf-1 downregulation imposed by hypoxia, both at the RNA and protein levels. Chromatin immunoprecipitation with HIF-1α and HIF-2α antibodies confirmed recruitment of HIF-α proteins to the two functional hypoxia-responsive elements on the native HSulf-1 promoter. HSulf-1 depletion in breast cancer cells resulted in an increased and sustained bFGF2 (basic fibroblast growth factor) signaling and promoted cell migration and invasion under hypoxic conditions. In addition, FGFR2 (fibroblast growth factor receptor 2) depletion in HSulf-1-silenced breast cancer cells attenuated hypoxia-mediated cell invasion. Immunohistochemical analysis of 53 invasive ductal carcinomas and their autologous metastatic lesions revealed an inverse correlation for the expression of HSulf-1 to CAIX in both the primary tumors (P ≥ 0.0198) and metastatic lesions (P ≥ 0.0067), respectively, by χ(2) test. Finally, HSulf-1 expression levels in breast tumors by RNA in situ hybridization showed that high HSulf-1 expression is associated with increased disease-free and overall survival (P ≥ 0.03 and P ≥ 0.0001, respectively). Collectively, these results reveal an important link between loss of HSulf-1 under hypoxic microenvironment and increased growth factor signaling, cell migration, and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.